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ABSTRACT 
 
 
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) having anti-
inflammatory and analgesic properties, and is widely used in the treatment of rheumatoid 
arthritis, osteoarthritis, and ankylosing spondylitis. One of the major problems with this 
drug is its low solubility in biological fluids, which results into poor bioavailability after 
oral administration. Therefore, solid dispersions (SDs) of aceclofenac were prepared 
using PEG6000, PVP and HPMC to increase its aqueous solubility. Aceclofenac SDs was 
prepared in 1:1, 1:2 and 1:1:1 ratios of the drug to polymer (by weight). In-vitro release 
profiles of all SDs (F-1 to F-9) were comparatively evaluated and also studied against 
pure aceclofenac. Faster dissolution was exhibited by solid dispersion containing (1:1:1) 
ratio of drug: PEG6000: PVP. The increase in dissolution rate of the drug may be due to 
increase in wettability, hydrophilic nature of the carrier and due to reduction in drug 
crystallinity.  The prepared solid dispersion was subjected for percentage practical yield, 
drug content, infrared (IR) spectroscopic and differential scanning calorimetry (DSC) 
studies. Absence of significant drug-carrier interaction was confirmed by infrared 
spectroscopic (IR) and differential scanning calorimetry (DSC) data. Solid dispersion of 
formulation (F7) aceclofenac, PEG 6000 and PVP combination prepared in (1:1:1) ratio 
showed excellent solubility and the dissolution rate was found to be 96.21% was selected 
as the best formulation in this study. 
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1.0 INTRODUCTION 
The enhancement of oral bioavailability of poorly water soluble drugs remains 
one of the most challenging aspects of drug development. There were several ways in 
which bioavailability of the drug can be enhanced all of which aimed at increasing the 
surface area of the drugs which includes. Micronization, use of salt form, use of 
metastable polymorphs, solvent deposition, selective adsorption on insoluble carriers, 
solid dispersion, solute solvent complexation and complexation with cyclodextrins.1 The 
development of solid dispersions as a practically viable method to enhance bioavailability 
of poorly water-soluble drugs overcame the limitations of previous approaches such as 
salt formation, solubilisation by co solvents and particle size reduction. 
   
The poor solubility and low dissolution rate of poorly water soluble drugs in the 
aqueous gastro-intestinal fluids often cause insufficient bioavailability.² Lipophilic 
molecules, especially those belonging to the bio-pharmaceutics classification system 
(BCS) class II and IV, dissolve slowly, poorly and irregularly, and hence pose serious 
delivery challenges, like incomplete release from the dosage form, poor bioavailability, 
increased food effect and high inter-patient variability.³   
 
 In 1961, Sekiguchi and Obi4 developed a practical method where by many of the 
limitations with the bioavailability enhancement of poorly water-soluble drugs just 
mentioned can be overcome. This method, which was later termed solid dispersion5, 
involved the formation of eutectic mixtures of drugs with water-soluble carriers by the 
melting of their physical mixtures6. Sekiguchi and Obi4 suggested that the drug was 
present in a eutectic mixture in a microcrystalline state. Later, Goldberg et al,7 
demonstrated that all the drug in a solid dispersion might not necessarily be present in a 
microcrystalline state; a certain fraction of the drug might be molecularly dispersed in the 
matrix, there by forming a solid solution. In either case, once the solid dispersion was 
exposed to aqueous media and the carrier dissolved, the drug was released as very fine, 
colloidal particles. Because of greatly enhanced surface area obtained in this way, the 
dissolution rate and the bioavailability of poorly water-soluble drugs were expected to be 
high.                        
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 The term solid dispersion refers to a group of solid products consisting of at least 
two different compounds, generally a hydrophilic matrix and a hydrophobic drug. The 
matrix can be either crystalline or amorphous. The drug can be dispersed molecularly, in 
amorphous particle (clusters) or in crystalline particles.8 
      
Solid dispersion can be prepared by various methods such as solvent evaporation 
and melting method. The mechanism by which the solubility and the dissolution rate of 
the drug are increased includes: reduction of the particle size of drug to submicron size or 
to molecular size in the case where solid solution is obtained. The particle size reduction 
generally increases the rate of dissolution; secondly, the drug is changed from amorphous 
to crystalline form, the high energetic state which is highly soluble, finally, the wettability 
of the drug particle is improved by the hydrophilic carrier.9 
        
  Solid dispersion of drug helps to reduce the particle size of drug due to molecular 
dispersion.10 Particle size reduction by micronization or nanonization can enhance the 
dissolution rate; however, the apparent solubility remains unaltered. At the molecular 
level, polymorphs offer a limited solubility advantage because of a small difference in 
free energy. In contrast, amorphous systems with excess thermodynamic properties and 
lower energetic barrier can offer significant solubility benefits.11   
 
 Aceclofenac (BCS Class II drug) is an orally effective non-steroidal anti-
inflammatory drug (NSAID) which possesses remarkable analgesic, antipyretic and anti-
inflammation in osteoarthritis and rheumatoid arthritis. It is a weakly acidic drug (pKa= 
4–5), practically insoluble in water and acidic pH conditions, but slightly solubility in 
basic pH conditions. There are certain problems coming with using aceclofenac as 
traditional oral tablet which includes bioavailability of aceclofenac is highly variable due 
to its low aqueous solubility and first pass metabolism. An increased solubilty with 
enhanced dissolution of the drug will improve its bioavailability. In order to improve the 
solubility, dissolution rate and bioavailability of the drug, it was attempted to prepare 
optimized aceclofenac solid dispersion. Previously several solid dispersion systems were 
prepared for the enhancement of solubility, dissolution rate, absorption rate and hence 
bioavailability of aceclofenac using Peg6000, Pvp ,Hpmc, Mannitol, Lactose, Urea, 
sodium citrate, Aeglemarmelos gum, β-cyclodextrins, and Poloxamer12. In the present 
study solid dispersions of aceclofenac were prepared with PEG 6000, PVP, HPMC each 
separately as well as in combination of these polymers and evaluated for physicochemical 
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and In-vitro release characteristics. This study will help understand the beneficial effects 
of polymers combination in comparison to individual polymers in improving the 
solubility, dissolution rate and bioavailability of aceclofenac solid dispersion.  
 
 
 
                                                
 
 
 
 
 
 
 
 
 
 
 
                                 
 
                                      
 
                          
4 
 
2.0 REVIEW OF LITERATURE 
Therapeutic effectiveness of a drug depends upon the bioavailability and 
ultimately upon the solubility of drug molecules. Solubility is one of the important 
parameters to achieve desired concentration of drug in systemic circulation for 
pharmacological response to be shown. Currently only 8% of new drug candidates have 
both high solubility and permeability.13The solubility of a solute is the maximum quantity 
of solute that can dissolve in a certain quantity of solvent or quantity of solution at a 
specified temperature. In other words the solubility can also be defined as the ability of 
one substance to form a solution with another substance. The substance to be dissolved is 
called as solute and the dissolving fluid in which the solute dissolve is called as solvent, 
which together form a solution. The process of dissolving solute into solvent is called as 
solution or hydration if the solvent is water.14The transfer of molecules or ions from a 
solid state into solution is known as dissolution.  
Dissolution of drug is the rate-controlling step which determines the rate and 
degree of absorption. Drugs with slow dissolution rates generally show erratic and 
incomplete absorption leading to low bioavailability when administered orally. Since 
aqueous solubility and slow dissolution rate of BCS class II and class IV drugs is a major 
challenge in the drug development and delivery processes, improving aqueous solubility 
and slow dissolution of these Classes of drugs have been investigated extensively15. A 
review of new monograph (1992-1995) in European pharmacopoeia shows that more than 
40% of the drug substances have aqueous solubility below 1mg/ml and the 32% have an 
aqueous solubility below 0.1mg/ml16, 17 
The dissolution rate of a drug is directly proportional to its solubility as per 
Noyes-Whitney equation and therefore solubility of a drug substance is a major factor 
that determines its dissolution rate and hence its absorption and bioavailability 
eventually18 
Noyes-Whitney equation illustrates how the dissolution rate of even very poorly 
soluble compounds might be improved to minimize the limitations to oral bioavailability: 
dc/dt = AD. (Cs - C) / h 
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Where, dc/dt is the rate of dissolution, A is the surface area available for 
dissolution, D is the diffusion coefficient of the compound, Cs is the solubility of the 
compound in the dissolution medium, C is the concentration of drug in the medium at 
time t, h is the thickness of the diffusion boundary layer adjacent to the surface of the 
dissolving compound19. 
 
TECHNIQUES OF SOLUBILITY ENHANCEMENT 20 
 
There are various techniques available to improve the solubility of poorly soluble 
drugs. Some of the approaches to improve the solubility are 
 
Micronization 
           Particle size reduction leads to increase in the effective surface area resulting in 
enhancement of solubility and dissolution velocity of the drug. 
 
Nanonization  
  Recently, various nanonization strategies have emerged to increase the dissolution 
rates and bioavailability of numerous drugs that are poorly soluble in water. Nanonization 
broadly refers to the study and use of materials and structures at the nano scale level of 
approximately 100 nm or less. Nanonization can result in improved drug solubility and 
pharmacokinetics; it might also decrease systemic side-effects. 
 
Nanocrystals  
 
The term drug nanocrystals imply a crystalline state of the discrete particles, but 
depending on the production method they can also be partially or completely amorphous. 
 
Nanosuspension 
Nanosuspensions are sub-micron colloidal dispersion of pure particles of drug, 
which are stabilised by surfactants. Nanosuspension technology solved the problem of 
drugs which are poorly aqueous soluble and less bioavailability. 
 
Nano emulsion  
 
Nanoemulsions are non-equilibrium, heterogeneous system consisting of two 
immiscible liquids in which one liquid is dispersed as droplets in another liquid. 
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Sonocrystallization 
 
Sonocrystallization is a novel particle engineering technique to enhance solubility 
and dissolution of hydrophobic drugs and to study its effect on crystal properties of drug. 
 
Supercritical fluid method 
   
A supercritical fluid (SCF) can be defined as a dense noncondensablefluid is 
another novel nanosizing and solubilisation technology whose application has increased 
in recent years. 
 
Spray freezing into liquid and lyophilization  
 
 This technique involves atomizing an aqueous, organic, aqueous-organic 
cosolvent solution, aqueous organic emulsion or suspension containing a drugand 
pharmaceutical excipients directly into a compressed gas (i.e. carbon dioxide, helium, 
propane, ethane), or the cryogenic liquids (i.e. nitrogen, argon or hydrofluroethers). 
 
Precipitation into aqueous solution  
This process utilizes rapid phase separation to nucleate and grow nanoparticles 
and microparticles of lipophilic drugs. 
 
Use of surfactant 
 Surface active agents (surfactants) are substances which at low concentrations, 
adsorb onto the surfaces or interfaces of a system and alter the surface or interfacial free 
energy and the surface or interfacial tension. 
 
Use of co-solvent 
 Co solvent addition is a highly effective technique for enhancement of solubility 
of poorly soluble drugs. It is well-known that the addition of an organic cosolvent to 
water can dramatically change the solubility of drugs. 
 
Hydrotropy method  
 
Hydrotropy is a solubilization phenomenon whereby addition of large amount of a 
second solute results in an increase in the aqueous solubility of another solute. The term 
“Hydrotropy” has been used to designate the increase in aqueous solubility of various 
poorly watersoluble compounds due to the presence of a large amount of additives. 
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Use of salt forms  
 
A major improvement in solubility and dissolution rate can be achieved by 
forming a salt. Salts of acidic and basic drugs have, in general, higher solubilities than 
their corresponding acid or base forms. 
 
Solvent deposition 
 
 In this technique drug is dissolved in a solvent like methylene chloride to produce 
a clear solution. The carrier is then dispersed in the solution by stirring and the solvent is 
removed by evaporation under temperature and pressure. 
 
Solubilizing agents 
 
Solubilizing materials like super disintegrants such crospovidone,crosscarmellose 
sodium and sodium starch glycolate used as solubilizing agents in many formulations 
which increase the solubilty and dissolution rate of poorly water soluble drugs. The 
superdisintegrants acts as hydrophilic carrier for poorly water soluble drug. 
 
Modification of the crystal habit  
 Polymorphism is the ability of an element or compound to crystallize in more 
than one crystalline form. Different polymorphs of drugs are chemically identical, but 
they exhibit different physicochemical properties including solubility, melting point, 
density, texture, stability etc. 
 
Co-crystallization 
The new approach available for the enhancement of drug solubility is through the 
application of the co-crystals, also referred as molecular complexes. 
 
Complexation 
The most common complexing ligands are cyclodextrins, caffeine, urea, 
polyethylene glycol, N methylglucamide. Considerable increase in solubility and 
dissolution of the drug has been achieved by the use of cyclodextrins. 
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CLASSIFICATION OF SOLID DISPERSION  
 First generation solid dispersions 
First generation solid dispersions were prepared using crystalline carriers such as 
urea and sugar, which were the first carriers to be employed in solid dispersion. They 
have the disadvantage of forming crystalline solid dispersion, which were 
thermodynamically more stable and did not release the drug as quickly as amorphous 
ones.21 
 
Second generation solid dispersions 
   Generation solid dispersions include amorphous carriers instead of crystalline 
carriers which are usually polymers. These polymers include synthetic polymers such as 
povidone (PVP),polyethylene glycols (PEG) and polymethacrylates as well as natural 
product based polymers such as hydroxy propyl methyl-cellulose (HPMC), , and 
hydroxypropoylcellulose or starch derivates like cyclodextrins.21 
 
Third generation solid dispersions 
 
        Recently, it has been shown that the dissolution profile can be improved if the 
carrier has surface activity or self-emulsifying properties. Therefore, third generation 
solid dispersions appeared. The use of surfactant such as inulin, inutec SP1, compritol 
888 ATO, gelucire 44/14 and poloxamer407 as carriers was shown to be effective in 
originating high polymorphic purity and enhanced in vivo bioavailability.21 
 
SIGNIFICANT PROPERTIES OF SOLID DISPERSION  
 
There are certain parameters that are given below when successfully controlled, 
can produce improvements in bioavailability22. 
 
Particle size reduction 
  Solid dispersion represents the last state of the size reduction. It includes the 
principle of drug release by creating a mixture of poorly water soluble drug and highly 
soluble carriers, and after dissolution of carrier, the drug get molecularly dispersed in 
dissolution medium. 
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 Wettability  
 Carriers having surface activity like cholic acid and bile salts, when used, can 
significantly increase the wettability properties of drug. Recently, in third generation solid 
dispersion surfactants have been included that is the emerging technique. 
 
 Higher porosity 
Solid dispersions containing linear polymers produce larger and more porous 
particles than those containing reticular polymers and therefore, result in a higher 
dissolution rate. 
 
Amorphous state of drug particles  
Drug particles in amorphous state have higher solubility. 
 
Approaches for avoiding drug recrystallization 
  Recrystallization is the major disadvantage of solid dispersions, as we are using 
amorphous drug particles and they are thermodynamically instable and have the tendency 
to change to a more stable state. Several polymers are being used for improving the 
physical stability of the amorphous drugs by increasing the Tg of the miscible mixture. 
 
CHARACTERISATION OF SOLID DISPERSION 
Solid dispersions are characterized for crystallinity and molecular structure in 
amorphous solid dispersion. Various different types of analytical methods are available to 
characterize solid dispersion.23 
Detection of crystallinity in solid dispersions 
 Many attempts have been to investigate the molecular arrangement in solid 
dispersions.  However, most effort has been put into differentiate between amorphous and 
crystalline material. For that purpose many techniques are available which detect the 
amount of crystalline material in the dispersion. The amount of crystalline material is 
never measured directly but is mostly derived from the amount of crystalline material in 
the sample. It should be noted that through the assessment of crystallinity as method to 
determine the amount of amorphous drug it will not be revealed whether the drug is 
present as amorphous drug particles or as molecularly dispersed molecule. 
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1. Powder x-ray diffraction (Xrd) 
                      2.  Infrared   Spectroscopy (IR) 
                      3.  Water Vapoursorption 
                      4.  Isothermal Microcalorimetry  
                      5.  Dissolution Calorimetry 
                      6.  Differential scanning Calorimetry (DSC) 
FACTORS AFFECTING SOLUBILITY24 
 
Particle size 
  The size of the solid particle influences the solubility because as a particle 
becomes smaller, the surface area to volume ratio increases. 
 
Temperature 
 Temperature will affect solubility. If the solution process absorbs energy then the 
solubility will be increased as the temperature is increased. 
 
Pressure 
 For gaseous solutes, an increased in pressure increases solubility and a decreases 
in pressure decreases the solubility. 
 
Nature of the solute and solvent 
   While only 1 gram of lead chloride can be dissolved in 100gm of water at room 
temperature, 200gm of zinc chloride can be dissolved. 
 
Molecular size  
   Molecular size will affect the solubility. The large molecule or the higher its 
molecular weight the less soluble the substance. 
 
Polarity 
  Polarity of the solute and solvent molecules will affect the solubility. 
 
Polymorphism 
  A solid has a rigid form and a definite shape. The shape or habit of a crystal of a 
given substance may vary but the angles between the faces are always constant.24 
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ADVANTAGES OF SOLID DISPERSION 
 Rapid dissolution rates that result in an increase in the rate and extent of the 
absorption of the drug, and a reduction in pre systemic both can lead to the need for lower 
doses of the drug. 
 Other advantages include transformation of the liquid form of the drug into a solid form 
(e.g., clofibrate and benzoyl benzoate can be incorporated into PEG 6000 to give a solid, 
avoidance of polymorphic changes and There by bio-availability problems), as in the case 
of nabilone and PVP dispersion, and protection of certain drugs by PEGs (e.g., cardiac 
glycosides) against decomposition by saliva to allow buccal absorption.22. 
 
 DISADVANTAGES OF SOLID DISPERSIONS 
The major disadvantages of SDs are related to their instability. Several systems 
have shown changes in crystallinity and a decrease in dissolution rate on ageing. By 
absorbing moisture, phase separation, crystal growth or a change from metastable 
crystalline form to stable form can take place which leads to the reduction of drug 
solubility .Moisture and temperature have more of deteriorating effect on solid 
dispersions than on physical mixtures. Sometimes it is difficult to handle because of 
tackiness.25 
 
LIMITATIONS OF SOLID DISPERSION 
The major limitation in the development of solid dispersion is the lack of suitable 
Manufacturing techniques that could be scaled up to commercial production. The various                        
limitations are: 22 
Laborious and expensive methods of preparation, 
Reproducibility of physicochemical characteristics, 
Difficulty in incorporating into formulation of dosage forms, 
Scale-up of manufacturing process,  
Stability of the drug and vehicle. 
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APPLICATIONS OF SOLID DISPERSION 
¾ To obtain a homogeneous distribution of a small amount of drug in solid state. 
¾ To stabilize the unstable drug. 
¾ To dispense liquid (up to 10%) or gaseous compounds in a solid dosage. 
¾ To formulate a fast release primary dose in a sustained released dosage form. 
¾ To increase the solubility of poorly soluble drugs thereby increase the dissolution 
rate, absorption and bioavailability.  
¾ To stabilize unstable drugs against hydrolysis, oxidation, recrimination 
isomerization, photo oxidation and other decomposition procedures.  
¾ To reduce side effect of certain drugs.  
¾ Masking of unpleasant taste and smell of drugs.  
¾ Improvement of drug release from ointment creams and gels.  
¾ To avoid undesirable incompatibilities.26, 
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Table: 1 Classification of carriers enhancing dissolution of drugs24 
 
 
 
S.NO 
 
CHEMICAL CLASS 
 
EXAMPLES 
1 Acids Citric acid, Tartaric acid, Succinic acid 
2 Sugars 
Dextrose, Sorbitol, Sucrose, Maltose, 
Galactose, Xylitol 
3 Polymeric Materials 
Polyvinylpyrrolidone, PEG-4000, PEG-
6000, Carboxymethyl cellulose, 
Hydroxypropyl  cellulose, Guar gum, 
Xanthan gum, Sodium alginate, 
Methylcellulose, HPMC, Dextrin, 
Cyclodextrins, Galactomannan 
4 Surfactants 
Polyoxyethylene stearate, Poloxamer, 
Deoxycholic acid, Tweens and Spans, 
Gelucire 44/14, Vitamin E TPGS NF 
5 Miscellaneous 
Pentaerythritol, Urea, Urethane, Hydroxy 
alkyl xanthine 
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Table: 2 Analytic methods for characterization of solid forms 
 
S.NO METHODS SIGNIFICANCE 
1. 
Thermal analysis 
Cooling Curve Method 
Thaw Melt Method 
Thermo microscopic Method 
Zone Melting Method 
DSC Studies 
DTA Studies 
To study the morphology and degree of 
crystallinity. 
To find out the interaction between drug and 
carrier and formation of inclusion complex.  
2. X-ray Powder Diffraction Studies
To find out the crystalline or amorphous 
form of drug. 
3. FTIR, NMR, Raman spectra 
To find out the complex formation between 
drug and carrier. 
4. Scanning Electron Microscopy To find out the particle size and shape. 
5. 
Dissolution rate /diffusion rate 
studies 
Rate and extent of dissolution. 
6. Thermodynamic study Degree of crystallinity 
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Fig.1 Methods of preparation of solid dispersion28 
 
SOLVENT EVAPORATION METHOD 
Though different methods have been followed for preparation of solid dispersion, 
the solvent evaporation method assumes significance in the present study and so a brief 
review of this method is presented. Commonly used method of preparing a solid 
dispersion is the dissolution of drug and carrier in a common organic solvent, followed by 
the removal of solvent by evaporation.29-31Because the drug used for solid dispersion is 
usually hydrophobic and the carrier is hydrophilic, it is often difficult to identify a 
common solvent to dissolve both compone3nts. Large volumes of solvents as well as 
heating may be necessary to enable complete dissolution of both components. Chiou and 
Riegelman29 used 500 mL of ethanol to dissolve 0.5 g of griseofulvin and 4.5g of PEG 
6000. Although in most other reported studies the volumes of solvents necessary to 
prepare solid dispersions were not specified, it is possible that they were similarly large. 
To minimize the volume of organic solvent necessary, Usui et al.32 dissolved a basic drug 
in a hydro alcoholic mixture of 1 N HCl and methanol, with drug to cosolvent ratios 
ranging from 1:48 to 1:20, because as a protonated species, the drug was more soluble in 
the acidic cosolvent system than in methanol alone. Some other investigators dissolved 
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only the drug in the organic solvent, and the solutions were then added to the melted 
carriers. Vera et al.33 dissolved 1g of oxodipine per 150mL of ethanol before mixing the 
solution with melted PEG 6000. In the preparation of piroxicam-PEG 4000 solid 
dispersion, Fernandez et al.34 dissolved the drug in chloroform and then mixed the 
solution with the melt of PEG 4000 at 70°C. Many different methods were used for the 
removal of organic solvents from solid dispersions. Simonelli et al.30evaporated ethanolic 
solvent on a steam bath and the residual solvent was then removed by applying reduced 
pressure. Chiou and Riegelman29 dried an ethanolic solution of griseofulvin and PEG6000 
in an oil bath at 115 °C until there was no evolution of ethanol bubbles. The viscous mass 
was then allowed to solidify by cooling in a stream of cold air. Other investigators used 
such techniques as vacuum-drying, 34, 35 spray-drying, 36-39 spraying on sugar beads using 
a fluidized bed-coating system, 40 lyophilization, 41 etc., for the removal of organic 
solvents from solid dispersions. None of the reports, however, addressed how much 
residual solvents were present in solid dispersions when different solvents, carriers, or 
drying techniques were used. 
 
Solvent  
Solvent to be included for the formulation of solid dispersion should have the 
following criteria: 
Both drug and carrier must be dissolved. 
Toxic solvents to be avoided due to the risk of residual levels after preparation  
E.g. chloroform and dichloromethane. 
Ethanol can be used as alternative as it is less toxic. 
Water based systems are preferred. 
Surfactants are used to create carrier drug solutions but as they can reduce glass transition 
temperature, so care must be taken in to consideration. 31 
 
Class I Solvents (Solvents to be avoided) 
   Solvents included in this class are not to be taken in to use because of their 
deleterious environmental effects. 
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    Table: 3 List of some Class I Solvents 
Solvent Concentration limit (ppm) Effect 
Benzene 2 Carcinogen. 
Carbon tetrachloride 4 Toxic and environmental 
Hazards. 
1,2-dichloroethane 5 Toxic. 
1,1-dichloroethane 8 Toxic. 
1,1,1-trichloroethane 1500 Environmental hazards. 
 
Class II Solvents (Solvents to be limited) 
 These solvent should be limited used in pharmaceutical products because of their 
inherent toxicity.  
 
            Table: 4 Class II Solvents in pharmaceutical products 
Solvent PDE(mg/day) Concentration limit(ppm) 
Chlorobenzene 3.6 360 
Chloroform 0.6 60 
Cyclohexane 38.8 3880 
1,2-dichloroethene 18.7 1870 
Ethylene glycol 6.2 620 
Methanol 30.0 3000 
Pyridine 2.0 200 
Toluene 8.9 890 
 
PDE= Permitted Daily Exposure 
 
Class III Solvents (Solvents with low toxic potential) 19 
 Solvents included in this class may be regarded as less toxic and have the low risk 
to human health. 
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  Table: 5 Class III solvents which should be limited by GMP or other quality based                
                                                                                requirements21            
 
 
 
 
 
 
 
 
 
 
 
 
Class IV Solvents (Solvents for which no adequate toxicological data was found)  
 Some solvents may also be of interest to manufacturers of excipients, drug 
substances or drug products for example Petroleum ether, isopropyl ether. However, no 
adequate toxicological data on which to base a PDE was found19. 
 
 
 
 
 
 
 
 
 
 
 
Acetic acid 
Acetone 
1-Butanol 
2-Butanol 
Butyl acetate 
Dimethyl sulfoxide 
Ethanol 
Ethyl acetate 
Ethyl ether 
Formic acid 
Heptane 
Isobutyl acetate 
Isopropyl acetate 
Methyl acetate 
3-Methyl-1-Butanol 
Pentane 
1-Pentanol 
1-Propanol 
2-Propanol 
Propyl acetate 
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 REVIEW OF PREVIOUS WORKS                                       
Sanjoy Kumar das et al developed and improving oral bioavailability of drugs 
those given as solid dosage forms remains a challenge for the formulation scientists due 
to solubility problems. The dissolution rate could be the rate-limiting process in the 
absorption of a drug from a solid dosage form of relatively insoluble drugs. Therefore 
increase in dissolution of poorly soluble drugs by solid dispersion technique presents a 
challenge to the formulation scientists. Solid dispersion techniques have attracted 
considerable interest of improving the dissolution rate of highly lipophilic drugs thereby 
improving their bioavailability by reducing drug particle size, improving wettability and 
forming amorphous particles. The term solid dispersion refers to a group of solid products 
consisting of at least two different components, generally a hydrophilic inert carrier or 
matrix and a hydrophobic drug. This article reviews historical background of solid 
dispersion technology, limitations, classification, and various preparation techniques with 
its advantages and disadvantages. This review also discusses the recent advances in the 
field of solid dispersion technology. Based on the existing results and authors’ reflection, 
this review give rise to reasoning and suggested choices of carrier or matrix and solid 
dispersion procedure.42 
 
Teresa Marın et al (2002) described as Flunarizine is a selective calcium entry 
blocker poorly water-soluble. In this report, the interactions of this drug with 
Polyvinylpyrrolidone in solid dispersions, prepared according to the dissolution method 
using methanol as the solvent, have been investigated. For purposes of comparison 
physical mixtures were prepared by simple mixture and homogenization of the two 
pulverized components. Combinations of flunarizine/Polyvinylpyrrolidone of the 
following percentage proportions were prepared: 10/90, 20/80, 30/70, 40/60, 50/50, 60/40 
and 80/20 (mean particle size of 0.175 mm). The physicochemical properties of solid 
dispersions were investigated with X-ray diffraction, infrared spectroscopy, differential 
scanning calorimetry and solubility in equilibrium. X-ray patterns and differential 
scanning calorimetry have shown that Polyvinylpyrrolidone inhibits the crystallization of 
flunarizine when percentages drug/polymer are 10/90, 20/80 and 30/70. The infrared 
spectra suggest that there was no chemical interaction between flunarizine and 
Polyvinylpyrrolidone. Equilibrium solubility studies showed that drug solubility was 
enhanced as the polymer content increased.43 
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Bikiaris et al (2005) developed a Polyvinylpyrrolidone (PVP) and poly (ethylene 
glycol) (PEG) solid dispersions with Felodipine or Hesperetin having up to 20 wt. % drug 
were prepared using solvent evaporation method. Solid dispersions in comparison with 
their physical mixtures were studied using differential scanning calorimetry (DSC), wide-
angle X-ray diffraction (WAXD), scanning electron microscopy (SEM) and hot stage 
polarizing light microscopy (HSM). PVP formulations with low drug load proved to be 
amorphous, since no crystalline Felodipine or Hesperetin drugs were detected using DSC 
and WAXD. Low and fast heating rates were applied for DSC study, to prevent changes 
in the samples caused during heating. Similarity between results of WAXD and DSC was 
also found in the case of physical mixtures, where the drug was in the crystalline state. 
However, though specific tests showed the high sensitivity of the DSC technique, it was 
difficult to arrive to reliable results for PEG solid dispersions or physical mixtures with 
low drug content by DSC, even by high heating rates. Crystalline drug could not be 
detected by DSC, leading to erroneous conclusions about the physical state of the drug, in 
contrast to WAXD. On the other hand, HSM proved the presence of small drug particles 
in the solid dispersions with PEG and the dissolution of the drug in the melt of PEG on 
heating. In such systems, in which a polymer with low melting point is used as drug 
carrier, DSC is inappropriate technique and must be used always in combination with 
HSM. The coupling of WAXD with thermal analysis, allowed complete physicochemical 
characterization and better understanding which is essential for a first prediction of 
dissolution characteristics of such formulations.44 
 
Sachin R. Patil et al (2009) developed an Aceclofenac is a novel non-steroidal 
anti-inflammatory drug (NSAID) having anti-inflammatory and analgesic properties and 
is widely used in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing 
spondylitis. One of the major problems with this drug is its low solubility in biological 
fluids, which results into poor bioavailability after oral administration. Therefore, solid 
dispersions (SDs) of aceclofenac were prepared using lactose, mannitol and urea to 
increase its aqueous solubility. Aceclofenac SDs were prepared in 9:1, 7:3 and 4:1 ratios 
of the drug to polymer (by weight). In vitro release profiles of all SDs (F-1 to F-9) were 
comparatively evaluated and also studied against pure aceclofenac. Faster dissolution was 
exhibited by SD containing 9:1 ratio of drug: lactose. The increase in dissolution rate of 
the drug may be due to increase in wettability, hydrophilic nature of the carrier and also 
due to reduction in drug crystallinity. The prepared SDs was objected for percent practical 
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yield, drug content and infrared (I.R) spectroscopic studies. Absence of significant drug 
carrier interaction was confirmed by I.R data.45 
 
Ravi Kumar et al (2010) reported an Aceclofenac is a novel non-steroidal anti-
inflammatory drug (NSAID) having anti-inflammatory and analgesic properties and is 
widely used in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing 
spondylitis. Difficulty in swallowing (dysphagia) is common among all age groups, 
especially in elderly and pediatrics. One of the major problems with this drug is its low 
solubility in biological fluids, which results into poor bioavailability after oral 
administration. Though aceclofenac is well absorbed after oral dosing, there is a first pass 
metabolism leading to a reduced bioavailability of the drug (40- 50%). Therefore, the 
present investigation was concerned to develop Mouth dissolving tablets of aceclofenac 
by effervescent formulation approach to provide patient friendly dosage form. The 
effervescent excipient system not only aids rapid disintegration of tablets in the oral 
cavity but also masks the slight bitter taste of medicament. Sodium bicarbonate, heat 
treated Sodium bicarbonate, tartaric acid, sodium glycine carbonate and citric acid were 
used as effervescent agents and their ratio in the formulation was optimized. The study 
revealed that 10:8 ratio of heat treated Sodium bicarbonate and citric acid (F3) in the 
Aceclofenac Mouth dissolving tablets gave a soothing fizz, excellent mouth feel, good 
palatability and quick dissolution profile. The optimized formulation (F3) was found to be 
stable during the stability studies conducted as per ICH guidelines, as it showed no 
significant changes (P<0.05) in the physicochemical properties, disintegration time and in 
vitro drug release.46 
 
Appa Rao. B et al, (2010) reported an Aceclofenac is a novel non-steroidal anti-
inflammatory drug (NSAID) having anti-inflammatory and analgesic properties, and is 
widely used in the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing 
spondylitis. One of the major problems with this drug is its low solubility in biological 
fluids, which results into poor bioavailability after oral administration. Therefore, solid 
dispersions (SDs) of Aceclofenac were prepared using lactose, mannitol and urea to 
increase its aqueous solubility. Aceclofenac SDs was prepared in 9:1, 7:3 and 4:1 ratios of 
the drug to polymer (by weight). In vitro release profiles of all SDs (F-1 to F-9) were 
comparatively evaluated and also studied against pure Aceclofenac. Faster dissolution 
was exhibited by solid dispersion containing 9:1 ratio of drug: lactose. The increase in 
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dissolution rate of the drug may be due to increase in wettability, hydrophilic nature of 
the carrier and due to reduction in drug crystallinity. The prepared solid dispersion was 
subjected for % practical yield, drug content and infrared (IR) spectroscopic studies. 
Absence of significant drug-carrier interaction was confirmed by infrared spectroscopic 
(IR) data.47 
 
Mohammed Gulzar Ahmed et al (2010) reported the present study is aimed at 
improving the dissolution of poorly water-soluble drug, aceclofenac. It is very slightly 
soluble in water and hence orally administered drug is less bioavailable. In order to 
enhance the bioavailability it is necessary to improve its solubility, hence the solid 
dispersion technique was adopted to enhance solubility. The solid dispersions were 
prepared in different proportions using hydrophilic carriers like Urea and Mannitol. The 
dissolution rate studies were performed in both simulated gastric fluid and simulated 
intestinal fluid. It is observed that the dissolution was affected by the acidity of the 
medium. Solid dispersions gave faster dissolution rate when compared to corresponding 
physical mixture and pure drug. In vivo absorption and anti-inflammatory activity studies 
of solid dispersions also confirmed the above results. The FTIR and DSC studies revealed 
that there is no interaction between drug and carriers and the drug, aceclofenac is stable in 
solid dispersions.48 
 
Aejaz A et al (2010) developed an Aceclofenac, an analgesic and anti-
inflammatory drug is used in treatment of osteoarthritis, rheumatoid arthritis and 
ankylosing spondylitis. Various compositions of Aceclofenac solid dispersions were 
prepared by physical mixing, fusion and solvent evaporation methods using. PVP, PEG 
6000, mannitol and urea as carrier to enhance the solubility of drug. The formulations 
evaluated for drug content, In-vitro dissolution study and also characterized by IR and 
DSC studies. There is no interaction between drug and carrier. The general trend 
indicated that there was a increase in In-vitro drug release for solid dispersion prepared in 
the following order Urea > PEG 6000 > PVP > Mannitol. Based on In-vitro drug release 
pattern, 1:3 drug carrier ratio was selected as ideal dispersion for gels. HPMC selected as 
ideal gel base for preparation of gels and dispersions are incorporated to gel bases by 
trituration. Formulations were characterized for rheological studies, drug content 
estimation and In-vitro diffusion study, IR spectroscopy. All these properties were found 
to be ideal.49 
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Kamal Dua et al (2010) developed the objective of the present investigation was 
to study the effect of various water soluble carriers like urea, mannitol, PVP and 
PVP/VA-64 on in vitro dissolution of aceclofenac from solid dispersions. Aceclofenac 
binary solid dispersions (SD) with different drug loadings were prepared using the 
melting or fusion method. In vitro dissolution of pure drug, physical mixtures and solid 
dispersions were carried out. Solid dispersion of aceclofenac with all four carriers (urea, 
mannitol, PVP and PVP/VA-64) showed considerable increase in the dissolution rate in 
comparison with physical mixture and pure drug in 0.1 N HCl, pH1.2 and phosphate 
buffer, pH, 7.4. FT-IR spectroscopy and differential scanning calorimetry studies 
indicated no interaction between aceclofenac and carriers in solid dispersions in solid 
state. Dissolution enhancement was attributed to decreased crystallinity of the drug and to 
the wetting, eutectic formation and solubilizing effect of the carrier from the solid 
dispersions of aceclofenac. In conclusion, dissolution of aceclofenac can be enhanced by 
the use of various hydrophilic carriers like urea, mannitol, PVP and PVP/VA-64.50 
 
Shobhit Kumar et al (2011) reported the aim of this study was to prepare and 
characterize solid dispersions of aceclofenac, employing a mixed excipient system 
composed of lactose, corn starch as a carrier and to study the effect of a mixed excipient 
system on rate of dissolution of drug. The solid dispersions were prepared by physical 
mixture method and solvent wetting method using 1:1 ratios of drug to mixed excipient 
system. The formulations were evaluated for % practical yield, drug content, bulk density, 
tapped density, Hauser’s ratio, Carr’s index, angle of repose and in vitro drug release. In 
this study it was concluded that there was considerable increase in in vitro drug release 
for solid dispersion as compared to the pure drug taken alone.  It was observed that the 
dissolution rate of drug from solid dispersions increases with the increase in lactose 
amount in comparison to corn starch with the optimum  ratio of (1.0) lactose:(0.5) corn 
starch showing the best result.51 
 
Ratna parkhi. M et al (2012) developed a Aceclofenac is new non-steroidal anti-
inflammatory drug acting by an inhibition of the synthetic of prostaglandins by inhibiting 
the activity of the enzyme, cyclooxygenase- 2(COX-2). It is more selective for COX –2 
than COX-1. Aceclofenac is practically insoluble in water and peak blood level release 
between 1.25 to 3 hrs after oral administration. It is practically insoluble in aqueous 
fluids. In the case of poorly -watersoluble drugs, dissolution is the rate-limiting step in the 
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process of drug absorption. The solid dispersion approach has been widely and 
successfully applied to improve the solubility, dissolution rates and consequently the 
bioavailability of poorly water-soluble drugs. To improve the dissolution of aceclofenac 
through the formulation of solid dispersion using water soluble carriers like mannitol by 
melt solvent methods and to convert the optimized solid dispersion in fast dissolving 
tablet formulation. The formulated tablets showed rapid in vitro drug dissolution and 
dissolution efficiency with in 30 min.52 
 
Reddy B. V et al (2012) reported in the present study, the aim was to enhance the 
oral bioavailability and dissolution rate of Aceclofenac by solid dispersions using 
polyethylene glycol (PEG-6000) as a carrier and to study the effect of carrier on 
dissolution rate. Initial studies were carried out using physical mixtures of the drug and 
carrier. Solid dispersions were prepared by fusion technique using dropping method. 
Aceclofenac was formulated as physical mixtures and solid dispersions (dropping 
method) using 1:2, 1:4, 1:6 and 1:8 ratios of drug and carrier (PEG 6000). Saturation 
solubility study for pure drug, physical mixtures and solid dispersions were carried out in 
water and pH 6.8 phosphate buffer solutions (PBS). PEG 6000 in 1: 8 drug to carrier ratio 
exhibited the highest drug release (98.69%) formulated as solid dispersions using 
dropping method. The FT-IR study shows that drug was stable in solid dispersions and 
there were no interactions. It is concluded that dissolution rate was improved by solid 
dispersion of aceclofenac: PEG 6000 prepared as 1:8 ratio by dropping method showed 
excellent physicochemical characteristics and was found to be described by dissolution 
release kinetics and was selected as the best formulation.53 
 
 Aminul Haque Md. et al (2012) reported the objective of the study was to 
improve the aqueous solubility and dissolution of carbamazepine, a poorly water soluble 
anti-epileptic drug by solid dispersion technique, using water soluble polymers. Solid 
dispersion of drugs was prepared by physical mixing, fusion and solvent evaporation 
method. The drug along with the polymers was heated first and then hardened by cooling 
to room temperatures. They were then pulverized, sieved, and then drug release was 
studied by the USP basket method at 75 rpm and 37±0.5°C. In this experiment sodium 
lauryl sulfate (SLS), acetone, hydroxy propyl cellulose (HPC), polyethylene glycol (PEG) 
6000, PEG 4000, poloxamer 407, hydroxy propyl methyl cellulose (HPMC) 6cps, HPMC 
15cps, Polyvinyl pyrrolidone (PVP) K30, PVP K12, and glyceryl monostearete (GMS) 
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were used as polymers. Distilled water was used as dissolution medium. The amount of 
drug was measured from the absorbance of UV spectrophotometer at 288 nm. The release 
of drug was plotted in zero order, 1st order, Hixson Crowell and Higuchi release pattern. 
The study shows that all the polymers enhanced the release profile of carbamazepine. The 
polymers are thought to serve as dispersing or emulsifying agents for the liberated drug, 
thus preventing the formation of any water-insoluble surface layers. The correlation 
coefficients values of the trend lines of the graphs showed that the formulations best fit in 
Higuchian release pattern.54 
 
Kumari R et al (2013) reported one of the favorable strategy to improve the 
solubility and hence bioavailability of poorly water soluble drugs is the formulation of 
solid dispersion. It refers to dispersion of an active ingredient in a carrier at solid state 
which is prepared by solvent evaporation method, melting method; melt solvent method, 
kneading method, co-grinding method, co-precipitation method, modified solvent 
evaporation method, spray drying, gel entrapment technique, and co-precipitation with 
supercritical fluid. On the basis of the carrier used in solid dispersion it is classified as 
first, second and third generation solid dispersions. As per biopharmaceutical 
classification system class II drugs are with low solubility and high permeability and are 
the promising candidates for improvement of bioavailability by solid dispersion. Some of 
the practical aspects to be considered for the preparation of solid dispersions, such as 
selection of carrier, molecular arrangement of drugs in solid dispersions are discussed.55 
                                                     
   Ramana B.V et al (2013)  developed  the aim of this study was to prepare and 
characterize solid dispersions of aceclofenac, employing a different excipient system 
composed of PEG6000, Glycine, and PVPk30 and to study the effect of a mixed excipient 
system on rate of dissolution of drug. The solid dispersions were prepared by physical 
mixture method and solvent wetting method using 1:1 ratios of drug to mixed excipients 
system. The formulations were evaluated for % practical yield, drug content, and in vitro 
drug release. In this study it was concluded that there was considerable increase in In-
vitro drug release for solid dispersion as compared to the pure drug taken alone. Based on 
the drug release pattern, the solvent wetting method showed more in vitro drug release as 
compared to physical mixture method. Finally it could be concluded that solid dispersion 
of Aceclofenac using hydrophilic polymers would improved the aqueous solubility, 
dissolution rate and thereby enhancing its systemic availability. 
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3.0 AIM AND OBJECTIVE 
AIM 
          To develop a solid dispersion of aceclofenac and improve the solubility of 
aceclofenac by using different carriers like PEG6000, PVP & HPMC to enhance the 
bioavailability of the drug. 
 
OBJECTIVE 
To estimate the following parameters.  
 Calibration curve of aceclofenac. 
 Preparation of solid dispersions (1:1, 1:2 and 1:1:1 ratios). 
 FTIR analysis of pure drug and solid dispersions. 
 DSC analysis of pure drug and solid dispersion. 
 Percentage Practical yield. 
 Drug Content estimation. 
 Phase solubility study. 
 In-vitro dissolution of pure drug, and solid dispersions. 
 Release kinetic study. 
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5.0 PROFILES 
5.1 DRUG PROFILE 
 
ACECLOFENAC57 
Drug                               :  Aceclofenac 
Chemical name               :  [2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy acetic 
                                                acid 
 
 
Structure                      :  
 
                                              
 
 
Formula   :      C16H13Cl12No4 
 
Molecular Weight  :       354.2 
 
Characters Appearance :     White or almost white, crystalline power. 
 
Melting point                      :      149-1500C 
 
Solubility                            :     practically insoluble in water, freely soluble in acetone,  
                                                      soluble in alcohol. 
 
Pharmacology                   
The mode of action of aceclofenac is largely based on the inhibition of 
prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclooxygenase, 
which is involved in the production of prostaglandins. 
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 The Drugs inhibits synthesis of the inflammatory cytokines interleukin (IL)-1 and 
tumor necrosis factor and prostaglandin E2 (PGE2) production. Effects on cell adhesion 
molecular from neurophils have also been noted. In vitro data indicate inhibition of 
cyclooxygenase (Cox)-1 and 2 by aceclofenac in whole blood assays, with selectivity for 
Cox-2 being evident. 
   Aceclofenac has shown stimulatory effects on cartilage matrix synthesis that may 
be linked to the ability of the drug to inhibit IL-1 activity. In vitro data indicate 
stimulation by the drug of synthesis of glycosaminoglycan in osteoarthritic cartilage. 
There is also evidence that aceclofenac stimulates the synthesis of IL-1 receptor 
antagonist in human articular chondrocytes subjected to inflammatory stimuli and that 4'-
hydroxyacelofenac has chondroprotective properties attributable to suppression of IL-1 
mediated promatrix metalloproteinase production and proteoglycan release. In patients 
with osteoarthritis of the knee, aceclofenac decrease pain reduces disease severity and 
improves the functional capacity of the knee. It reduces joint inflammation, pain intensity 
and the duration of morning stiffness in patients with rheumatoid arthritis. The duration of 
morning stiffness and pain intensity are reduced and spinal mobility improved, by 
aceclofenac in patients with ankylosing spondylitis. 
Pharmacokinetics 
  Aceclofenac is rapidly and completely absorbed after oral administration, peak 
plasma concentrations are reached 1 to 3 hours after an oral dose. The drug is highly 
protein bound (99.7%). The presence of food does alter the extent of absorption of 
aceclofenac but the absorption rate is reduced. The plasma concentration of aceclofenac 
was approximately twice that in synovial fluid after multiple doses of the drug in-patient 
with knee pain and synovial fluid effusion. Aceclofenac is metabolized to a major 
metabolite, 4'-hydroxyaceclofenac and to a number of other metabolites including 5-
hydroxyaceclofenac, 4'-hydroxydiclofenac, diclofenac and 5-hydroxydiclofenac. Renal 
excretion is the main route of elimination of aceclofenac with 70 to 80% of an 
administered dose found in the urine, mainly as the glucuronides of aceclofenac and its 
metabolites of each dose of aceclofenac, 20% is excreted in the faces. The plasma 
elimination half-life of the drug is approximately 4 hours. 
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Summary of pharmacokinetics 
 
 Volume of distribution 25lit 
 
 Plasma half-life:2.5-4.0hrs 
 
 Plasma protein binding: 99.7% 
 
 Dose: 100mg twice daily 
 
Drug Interactions 
 Aceclofenac may increase plasma concentrations of lithium, digoxin and 
methotrexate, increase the activity of anticoagulant, inhibits the activity of diuretics, 
enhance cyclosporine nephrotoxicity and precipitate convulsions when co-administered 
with quinolone antibiotics. Furthermore, hypo or hyper glycaemia may result from the 
concomitant administration of aceclofenac and antidiabetic drugs, although this is rare. 
The co administration of aceclofenac with other NSAIDS of corticosteroids may results in 
increased frequency of adverse event. 
 
Adverse Drug Reaction 
  Aceclofenac is well tolerated, with most adverse events being minor and 
reversible and affecting mainly the GI system. Most common events include dyspepsia 
(7.5%), abdominal pain (6.2%), nausea (1.5%), diarrhea (1.5%), flatulence (0.8%), 
gastritis (0.6%), constipation (0.5%), vomiting (0.5%), ulcerative stomatitis (0.1%), and 
pancreatitis (0.1%). 
           Although the incidence of gastro intestinal adverse events with aceclofenac was 
similar to those of comparator NSAIDS in individual clinical trials, withdrawal rates due 
to these events were significantly lower aceclofenac than with ketoprofen and tenoxicam.   
Other adverse effect, which is not common such as dizziness (1%), vertigo (0.3%), and 
rare cases: par aesthesia and tremor. 
Therapeutic uses 
Aceclofenac significantly reduced pain and improves functional capacity and 
mobility relative to baseline in patients with osteoarthritis, rheumatoid arthritis or 
ankylosing spondylitis and reduces inflammation in patients with rheumatoid arthritis. No 
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head to head comparison between Aceclofenac and coxibs have been performed, nor for 
efficacy neither for tolerance. 
Aceclofenac in osteoarthritis 
         In patients with osteoarthritis of the knee, aceclofenac decreases pain, reduces 
disease severity and improves the functional capacity of the knee to a similar extent to 
diclofenac, piroxicam, and naproxen. 
Aceclofenac in rheumatoid arthritis 
          The anti-inflammatory and analgesic efficacy of aceclofenac is similar to that of 
ketoprofen, indomethacin, tenoxicam and diclofenac in patients with rheumatoid arthritis. 
In randomized, double blind trials in 169 to 261 patients, aceclofenac (100 mg twice daily 
for 3 or 6 months) significantly reduced relative to baseline joint inflammation, pain 
intensity and the duration of morning stiffness and improved handgrip strength. 
Aceclofenac in ankylosing spondylitis 
   The duration of morning stiffness and pain intensity are reduced and spinal 
mobility improved, by aceclofenac in patients with ankylosing spondylitis, with 
improvements being similar to those observed with indomethacin, naproxen or 
tenoxicam. These effects were observed after aceclofenac 100 mg twice daily for 3 
months in randomized, double blind trials involving 104 to 308 patients. 
Aceclofenac in dental pain 
  The analgesic efficacy as single doses of aceclofenac has been assessed in patients 
with moderate to severe tooth pain and in extraction of impacted third molars. The 
analgesic efficacy of single doses of aceclofenac 50, 100 and 150 mg was greater than 
that of place in patients with moderate to severe tooth pain or pain caused by extraction of 
impacted third molars. 
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Aceclofenac in postoperative pain 
 The analgesic efficacy of aceclofenac has been shown in comparisons with 
paracetamol in women undergoing episiotomy. Aceclofenac 100 mg was superior to 
paracetamol 650 mg in providing relief from post episiotomy pain, particularly 3 to 5 
hours after ingestion. 
Aceclofenac in Dysmenorrhea 
   In a more recent non comparative study in 1338 women with dysmenorrhea 
treated for first 3 days of 2 consecutive cycles. 
Aceclofenac in acute lumbago 
  Aceclofenac (150 mg intramuscularly for 2 days, then 100 mg orally, both twice 
daily) was superior to diclofenac in alleviating functional impairment in a 7 days study in 
100 patients with acute lumbago. Aceclofenac 100 mg twice daily was associated with 
symptomatic relief of acute low back pain in a non-comparative study in 67 patients. 
Aceclofenac in musculoskeletal trauma 
 Aceclofenac 100 mg twice daily has also been assessed in patients with 
musculoskeletal trauma, although only non-comparative studies are available. 
Aceclofenac Gonalgia (Knee pain) 
A controlled double blind study was performed with aceclofenac comparing it 
with diclofenac in 40 patients with acute or chronic gonalgia. The results of the trial 
indicate slightly superior activity, although there was no statistically significant difference 
between two drugs. 
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5.2 POLYMER PROFILE 
(A) Polyethylene Glycol (PEG 6000)58 
 
 Specifications; 
               Average molecular 
               Weight 
         : 5000-7000 
               pH of5% Aq. Sol   : 4-7 
               Freezing  Point           : 56-630C 
              Viscosity at1000C : 470-900CST 
Properties and Applications   
PEG-6000 is a high molecular weight polymer of ethylene oxide and is a blend of 
polymers with different degrees of polymerization. Like all other PEGs, PEG -6000 is 
readily soluble in water. So water can be the most economical solvent for this, apart from 
other organic solvents. PEG-6000 acts as binder and dry lubricant due to its laminar 
structure and therefore can be used in the manufacture of pills and tablets for certain 
pharmaceutical preparations. In rubber industry, PEG-6000 can be used as a mould 
release agent. A solution of PEG 6000 can be used as a mould release agent. A solution of 
PEG 6000 of 3-20% concentration can be coated or sprayed into the hot mould cavities, 
thus enabling the solvent to evaporate , the solution is either dried by applying heat or 
allowed to dry evaporate ,the solution is either dried by applying heat or allowed to dry 
evaporation of solvent. Other applications of PEG -6000 include as wetting agents to 
inhibit soap cracking, as binder for facial makeup, as anti-dusting agent for after bath 
talcum powder, lubricant in paper industry, as a tire mounting agent, as an additive in 
grease, as plasticizer in synthetic resin, as enhancer of thermal stability in adhesive 
preparations, as an additional component of galvanization bath etc. for copper and nickel 
electroplating of steel and iron parts. PEGs being non-ionic products, facilitate the even 
distribution of electrolytes.PEG6000 dissolved in lower glycols in place of paraffin wax 
are used for embalming of histological and other medical specimens. 
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Compatibility 
  
Compatibility of glycols is proved to be good in formulations of Nitrofurazone, 
Undencanoic acid, Sulphur, Hydrocortisone, Methyl Salicylate, Benzyl Benzoate etc. 
 
Incompatibility 
 
         Glycols are not compatible with Penicillin, Bacitracin, Iodine, potassium iodide, 
Sorbitol, Tannic acid, Bismuth salts. Glycols are also not suitable with Poly ethylene, 
Backlit and celluloid. 
 
Packing 
        25 KG Net in pp. woven bags. 
 
Storage 
        Under dry conditions and at room temperature in sealed containers. 
 
Stability 
        Stable under ordinary conditions of use and storage. 
 
Hazardous decomposition products: 
        Carbon dioxide and carbon monoxide may form when heated to decomposition. 
 
Hazardous polymerization 
  Will not occur. 
 
Incompatibilities 
  Incompatible with polymerization catalysts (peroxides, per sulfates) and 
accelerators, strong oxidizers, strong bases and strong acids. 
 
Conditions to avoid  
   In compatibilities. 
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(B) Polyvinylpyrrolidone59 
  
Synonym                    :     Poly [1-(2-oxo-1-pyrrolidinyl) ethylene]; polyvidone;                             
                                                       Polyvinylpyrrolidone;pvp;1-vinyl-2-pyrrolidinone   
                                                        Polymer 
 
 Chemical name         :    1-Ethenyl-2-pyrrolidinone homo polymer. 
Empirical Formula    :     (C6H9NO)n 
Molecular Weight      :     40000(approximately) 
Structural Formula  : 
 
                                        
 
 
Description                :    povidone occurs as a fine, white to creamy-white colored,                                
                                          odorless. 
Typical properties     
  Acidity/alkalinity    :    pH=3.0-7.0(5%w/v aqueous solution). 
  Flow ability             :    20g/s for povidone k-15; 1620g/s for povidone k-29/32. 
 Melting point           :    softens at 1500c. 
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Moisture content 
 Povidone is very hygroscopic, significant amounts of moisture being absorbed at 
low relative humidity. 
Solubility 
 Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and water; 
practically insoluble in ether hydrocarbons, and mineral oil. In water, the concentration of 
a solution is limited only by the viscosity of the resulting solution, which is a function of 
the polymer. 
Viscosity (dynamic) 
 The viscosity of aqueous povidone solutions depends on both the concentration 
and    the molecular weight of the polymer employed. 
Functional Category 
 Disintegrent; dissolution aid; suspending agent; tablet binder 
Applications                                                                                     
   It is used as a binder in many pharmaceutical tablets It simply through the body 
when taken orally. 
It is used in pleurodesis. 
It is used as an adhesive in glue stick and hot-melt adhesive. 
As an emulsifier and Disintegrent for solution polymerization  
Used in aqueous metal quenching. 
As a thickening agent in tooth whitening gels. 
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(C) Hydroxy Propyl MethylCellulose60 
 
Synonyms             :            Methyl hydroxypropyl cellulose, methylcellulose  
                                                  propylene glycol ether. 
                                       
Chemical name    :            Cellulose, 2- Hydroxy propyl methyl ether 
BP                          :             Hypromellose 
USP                       :             Hydroxy propyl methyl cellulose 
 
Chemical structure 
                                            
Molecular weight     :         Molecular weight is approximately 10,000-1, 50,000. 
Empirical Formula 
          Hydroxypropylmethylcellulose is partly O-methylated and O-(2-hydroxy 
propylated) cellulose. It is available in several grades which vary in viscosity and extent 
of substitution. 
Functional category 
 Coating agent, film-former, rate controlling polymer for sustained release, 
stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
Applications 
          Hydroxy propyl methyl cellulose is widely used in oral and topical pharmaceutical 
formulation. In oral products, hydroxy propyl methyl cellulose is primarily used as an 
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extended release tablet matrix. High viscosity grades may be used to retard the release of 
drugs from a matrix at levels 10-80%w/w in tablets and capsules. 
Description 
         Hydroxy propyl methyl cellulose is an odorless and tasteless, white or creamy-white 
colored fibrous or granular powder. 
Typical properties 
Bulk Density                   : 0.341 g/cc            
Viscosity                         : 80,000-1, 20,000 cps 
Methyl Content              : 19-24%       
Tap density                     : 0.557 g/cc 
Specific Gravity              :  1.26 g/cc 
Hydroxy propyl content  :  7-12% true density:1.326 g/cc 
Melting point                   :  Browns at 190-2000C; chars at 225-2300C. 
Moisture Content 
Hydroxy propyl methyl cellulose  absorbs moisture from the atmosphere, the 
amount of water absorbed depending upon the initial moisture content and temperature 
and relative humidity of the surrounding air. 
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6.0 MATERIALS AND INSTRUMENTS 
INGREDIENTS USED 
Table: 6 Ingredients used for the experiment 
S. No Name of the ingredient Manufacturer/Suppliers 
1. Aceclofenac Dr.Reddy’s laboratory  (Hyderabad) 
2. Polyethylene glycol(PEG6000) Yarrow chemicals laboratory 
(Mumbai) 
3. Polyvinylpyrrolidone Loba chemie pvt.ltd (Mumbai) 
4. Hydroxypropyl methylcellulose Loba chemie pvt.ltd (Mumbai) 
5. Methanol Finar chemicals ltd (Mumbai) 
   
 INSTRUMENTS USED 
Table: 7 Instruments used for the experiment 
S. No Name of the instrument Manufacturing company 
 
1. 
 
UV – visible Spectrophotometer 
 
Perkin Elmer lamda25 (USA) 
 
2. 
 
FT-IR Spectrophotometer 
 
Perkin Elmer spectrum RX1 (USA) 
 
3. 
 
Differential Scanning Calorimetry 
 
DSC DA 609 Shimadzu (Japan) 
 
4. 
 
Single pan digital Balance 
 
Schimadzu BL 220H (Japan) 
5. Programmable dissolution Apparatus 
(USP) 
 
Veego (Mumbai) 
6. Magnetic stirrer Eltek MS 2012 (Mumbai) 
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7.0 METHODOLOGY 
 
7.1 CONSTRUCTION OF STANDARD CURVE FOR ACECLOFENAC 
 
  This method was adapted to pure aceclofenac 100mg was accurately weighed and 
dissolved in phosphate buffer (pH 6.8). Further, dilutions were made to get 2,4,6,8 
&10µg/ml the sample point 275 nm. A standard curve was constructed by plotting the 
absorbance vs. concentration of the drug taken47. 
Preparation of PH 6.8 phosphate buffer  
Placed 50 ml of 0.2 M Potassium dihydrogen phosphate in a 200 ml volumetric 
flask, added specified volume of 22.4 ml of 0.2 M NaOH and then added water to make 
the volume. 
0.2 M Potassium dihydrogen phosphate 
Dissolve 27.218 gm of potassium dihydrogen phosphate in distilled water and 
dilute to 1000 ml with distilled water. 
0.2 M NaOH solution 
 Dissolved 8 gm of NaOH in distilled water and diluted to 1000 ml with distilled 
water. 
7.2 PREPARATION OF SOLID DISPERSION 
            Aceclofenac solid dispersion were prepared by using hydrophilic carriers like 
polyethylene glycol (PEG6000) Polyvinylpyrrolidone and Hydroxypropyl 
methylcellulose in proportions viz .1:1 (drug: carrier) (50mg:50mg), 1:2 (50mg: 100mg) 
and 1:1:1 (drug:carrier:carrier) (50mg: 50mg: 50mg) was prepared by solvent evaporation 
method. Aceclofenac and carriers were dissolved in methanol and mixed with magnetic 
stirring. Solvent was evaporated at reduced pressure at 40oC in a rotatory evaporation 
apparatus. Subsequently solid dispersion was stored under vacuum over silica gel for 12 
hrs at room temperature. After drying the solid dispersion was passed through a 250µm 
sieve. Sample was stored in a desiccator and used for further investigation61. 
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 Table: 8 Formulation of aceclofenac solid dispersion 
S.NO FORMULATION COMPOSITION 
DRUG : 
CARRIER 
1 F1 
Aceclofenac+ 
polyethyleneglycolate(PEG6000) 
1:1 
2 F2 
Aceclofenac+ Polyvinylpyrrolidone 
(PVP) 
1:1 
3 F3 
Aceclofenac+  
Hydroxypropylmethylcellulose (HPMC) 
1:1 
4 F4 
Aceclofenac+ polyethylene 
glycol(PEG6000) 
1:2 
5 F5 
Aceclofenac+ Polyvinylpyrrolidone 
(PVP) 
1:2 
6 F6 
Aceclofenac+  
Hydroxypropylmethylcellulose (HPMC) 
1:2 
7 F7 
Aceclofenac+polyethyleneglycol+ 
Polyvinylpyrrolidone 
1:1:1 
8 F8 
Aceclofenac+Polyethylene glycol+  
Hydroxypropylmethylcellulose 
1:1:1 
9 F9 
Aceclofenac+ Polyvinylpyrrolidone 
Hydroxypropylmethylcellulose 
1:1:1 
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7.3 EVALUATION OF FORMULATIONS   
The prepared formulations of solid dispersions were evaluated for the following     
  Physico chemical characterization 
   In-vitro dissolution studies      
7.3.1 PHYSICO CHEMICAL CHARACTERIZATION 
Compatibility study 
        Fourier transform infrared spectroscopy was employed to characterize the possible 
interactions between the aceclofenac and carriers. In this study pure drug, solid 
dispersions were studied by FTIR spectrophotometer. 
 Differential Scanning Calorimetry (DSC) 
Differe ntial scanning calorimetry (DSC) curve of aceclofenac, PEG6000, PVP, 
HPMC, physical mixture and solid dispersions were measured with a DSC instrument 
(Mettler Tolero Model). The samples were accurately weighed and heated in closed 
aluminum crimped cells at a rate of 10oC.min-1 between 30 and 300oC temperature under a 
nitrogen gas flow of 40mL.min-1during study. 
 Drug content estimation 
        Solid dispersions equivalent to 10 mg of aceclofenac were weighed accurately and 
dissolved in the 10 ml of methanol. The solution was filtered, diluted suitably and drug 
content was analyzed at 275 nm by UV spectrophotometer. The Actual Drug Content was 
calculated using the following equation as follows62: 
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Percentage Practical Yield 
Percentage practical yield was calculated to know about percent yield or 
efficiency of any method, thus its help in selection of appropriate method of production. 
Solid dispersions were collected and weighed to determine practical yield (PY) from the 
following equation 63.  
 
7.3.2 Determination of phase solubility of Aceclofenac 
   Drug solubility studies were performed in triplicate by adding excess amount of 
aceclofenac to methanol and buffer solutions having different pH (6.8). Solutions 
containing flasks were kept on a Rotary Shaking Incubator for 24 hrs. After 24 hrs, 
solutions were analyzed using UV spectrophotometer64. 
7.3.3 In-vitro Dissolution study 
 In-vitro dissolution studies of the pure drug (aceclofenac), the selected ratios of 
solid dispersions (equivalent to 50mg aceclofenac filled in hard gelatin capsules using 
stainless steel sinkers) were performed using USP type II (Paddle) apparatus with paddle 
rotating at 50 rpm in 900ml of phosphate buffer pH 6.8 at 37 ± 0.5ºC. At fixed time 
intervals, 5ml samples were withdrawn, filtered and replaced with phosphate buffer pH 
6.8. Concentration of aceclofenac in each sample was determined by UV 
spectrophotometer47. 
KINETIC ANALYSIS OF IN -VITRO RELEASE RATES OF FORMULATIONS65, 66 
 The results of in-vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows:- 
Zero-order kinetic model-cumulative percentage drug release versus time. 
First- order kinetic model-log cumulative percentage drug release remaining versus time. 
Higuchi's model-cumulative percentage drug released versus square root of time. 
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Korsmeyer’s equation/peppa's model-log cumulative percentage drug released versus log 
time. 
 
1. Zero-order kinetics 
          Zero order release would be predicted by the following equation:- 
At = A0 - K0 t 
Where, 
                 At = Drug release at time‘t’ 
                 A0 = Initial drug concentration 
                 K0 = Zero order rate constant (hr-1) 
          When the data is plotted as cumulative percent drug release versus time, if the plot 
is linear then the data obeys zero-order release kinetics, with a slope equal to K0. 
2. First- order kinetics 
          First-order release would be predicted by the following equation:- 
Log C = log C0 - Kt /2.303 
 Where, 
                C=Amount of drug remained at time‘t’ 
                C0=Initial amount of drug 
                K=First-order rate constant (hr-1 
 When the data is plotted as log cumulative percent drug remaining versus time 
yields a straight line, indicating that the release follow first order kinetics. The constant K 
can be obtained by multiplying 2.303 with slope values. 
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3. Higuchi's model 
         Drug release from the matrix devices by diffusion has been described by following 
Higuchi's classical diffusion equation. 
Q = [Dε /τ(2A - εCs) Cst]1/2 
  Where, 
              Q=Amount of drug released at time‘t’ 
              D=Diffusion coefficient of drug in the matrix 
              A=Total amount of drug in unit volume of matrix 
              Cs= The solubility of drug in the matrix 
              ε= Porosity of the matrix 
              τ= Tortuosity 
               t= Time (hrs) at which Q amount of drug is released 
          Above equation may be simplified if one assumes that D, Cs, and A, are constant. 
Then equation becomes: 
Q = K t ½ 
  When the data is plotted according to equation i.e. cumulative drug release versus 
square root of time yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to 'K'. 
4. Korsmeyer’s equation/ peppa's model                         
 To study the mechanism of drug release from the solid dispersions, the release 
data were also fitted to the well-known exponential equation (Korsmeyer’s 
equation/peppa's law equation), which is often used to describe the drug release behavior 
from polymeric systems. 
Mt/Ma = Ktn 
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 Where, 
Mt/Ma = The fraction of drug released at time‘t’ 
K= Constant incorporating the structural and geometrical characteristics of  the 
drug/polymeric 
N= Diffusion exponent related to the mechanism of release 
Above equation can be simplified by applying log on both sides, and we get: 
Log Mt/Ma = Log K +n Log t 
          When the data is plotted as log of drug released versus log time, yields a straight 
line with a slope equal to 'n' and the 'K' can be obtained from y-intercept. For Fickian 
release 'n' =0.5 while for anomalous (non-Fickian) transport 'n' ranges from 0.5 to 1.0 as 
shown below. 
        Table: 9 Mechanism of drug release as per korsemeyer equation/peppa's model 
S.No n Value Drug release 
1. n < 0.5 Fickian release 
2. 0.5<n<1 Non- Fickian release 
3. n>1 Case II transport 
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8.0 RESULTS AND DISCUSSION 
COMPATABILITY STUDY 
     The FTIR spectra of pure aceclofenac, carriers, physical mixture of drug and carriers 
and solid dispersion of drug and carrier are shown in Tables- 10-15 and Figures 2-7. The 
spectra exhibited presence of characteristic peaks of drugs in physical mixture and indicate 
that there was no chemical interaction between the drugs. 
         Fig.2 FTIR SPECTRA OF PURE ACECLOFENAC 
 
     Table: 10 
 
 
S.no 
 
 
IR Spectrum 
 
Peaks(cm-1)
 
Groups 
 
Stretching 
/Deformation 
 
 
 
1 
 
 
 
ACECLOFENAC 
 
 
3319.38 O-H(Alcohol) 
 
Stretching 
1717.09 C=O(Carbonyl) Stretching 
 
1158.09 C-N(Amine)  
 
Stretching 
745.17 C-Cl(Alkyl halide) Stretching 
 
48 
 
       Fig.3 FTIR SPECTRA OF PURE POLYETHYLENE GLYCOL 6000 
 
    Table: 11 
 
 
S.no 
 
 
IR Spectrum 
 
 
Peaks(cm-1) 
 
Groups 
 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
PEG6000 
 
 
3446.54 O-H(Alcohol) 
 
Stretching 
2889.37 C-H(Alkane) Stretching 
 
1640.10 C=O(Amide)  
 
Stretching 
542.79 C-BR(Alkyl halide) Stretching 
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         Fig.4 FTIR SPECTRA OF PURE POLYVINYL PYRROLIDONE 
Table: 12 
 
 
S.no 
 
 
IR Spectrum 
 
 
Peaks(cm-1) 
 
Groups 
 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
PVP 
 
 
3463.99            O-H(Alcohol) 
 
Stretching 
1674.24      C=C(Alkene) Stretching 
 
1062.36           C-F(Alkyl halide)  
 
Stretching 
573.42      C-Br(Alkyl halide) Stretching 
       
 
 
         
             
 
   
50 
 
     Fig.5 FTIR SPECTRA OF PURE HYDROXYPROPYL METHYLCELLULOSE 
 
    Table: 13 
 
 
S.no 
 
 
IR Spectrum 
 
 
Peaks(cm-1) 
 
Groups 
 
Stretching 
/Deformation 
 
 
 
1 
 
 
 
HPMC 
 
 
2987.04       C-H(Alkane) 
 
Stretching 
1689.87 C=O(Carbonyl) Stretching 
      1297.58       C-F(Alkyl halide) 
 
 
Stretching 
       1059.28       C-F(Alkyl halide) Stretching 
         
 
 
 
      
 
51 
 
Fig.6 FTIR SPECTRA OF PHYSICAL MIXTURE OF ACECLOFENAC,          
PEG6000, PVP AND HPMC 
 
 
    Table: 14 
 
 
S.no 
 
 
IR Spectrum 
 
Peaks(cm-1)
 
Groups 
 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
Physical mixture 
 
 
3271.44           O-H (Alcohol) 
 
Stretching 
1712.09      C=o (Carbonyl) Stretching 
 
1099.17  C-N(Amine)  
 
Stretching 
744.67   C-Cl(Alkyl halide) Stretching 
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Fig.7 FTIR SPECTRA OF SOLID DISPERSION OF ACECLOOFENAC,   
PEG6000, PVP AND HPMC 
 
 
    Table: 15 
 
 
S.no 
 
 
IR Spectrum 
 
Peaks(cm-1)
 
Groups 
 
Stretching 
/Deformation 
 
 
 
 
1 
 
 
 
Solid dispersion 
 
 
3270.38 O-H (Alcohol) 
 
Stretching 
1711.50      C=o (Carbonyl) Stretching 
 
1138.58         C-F(Alkyl halide)  
 
Stretching 
744.83   C-Cl(Alkyl halide) Stretching 
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DIFFERENTIAL SCANNING CALORIMETRY 
 In the DSC studies of pure aceclofenac showed a sharp endotherm at 152.51oC, 
PEG6000 at 62.50oC, PVP at 218.76 oC, Hpmc at 122.8oC and physical mixture at 160oC 
to its melting point. There was no appreciable change in the melting endotherm of 
spherical agglomerates compared to that of pure drug (F7 agglomerates =153.270C) the 
DSC results also revealed little amorphization of aceclofenac when compared in the form 
of agglomerates with PEG6000 and PVP combination. 
 
 
                                  Fig.8 DSC THERMO GRAM OF PURE ACECLOFENAC 
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                                       Fig.9 DSC THERMO GRAM OF PURE PEG6000 
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                                         Fig.10 DSC THERMO GRAM OF PURE PVP 
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                                              Fig.11 DSC THERMO GRAM OF PURE HPMC 
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                                  Fig.12 DSC THERMO GRAM OF   PHYSICAL MIXTURE 
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                             Fig.13 DSC THERMO GRAM OF F7 FORMULATION 
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CALIBRATION CURVE OF ACECLOFENAC 
   The calibration curve of aceclofenac was determined in pH 6.8 phosphate buffer 
by using UV-Visible spectrophotometer at 275 nm. Graph was plotted by taking 
absorbance (nm) on X-axis verses concentration (µg/ml) on Y-axis and it is follows the 
Beer's law. The results were shown in table: 16. 
          Table: 16 Calibration curve of aceclofenac 
Sl.no Concentration of 
aceclofenac(µg/ml) 
 
Absorbance at     
275nm 
0                  0             0 
1                  2 0.05541 
2                  4 0.1047 
3                  6 0.1564 
4                  8 0.2019 
5                 10 0.2624 
R2 value  0.9988 
                                  
y = 0.0259x 
R² = 0.9988 
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Fig. 14 Calibration curve of aceclofenac 
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DRUG CONTENT ESTIMATION 
Drug content uniformity of aceclofenac solid dispersion in all the formulations 
(F1 to F9) were shown from 66.5±0.7071 to 87.09±3.7390 respectively.62As shown in 
table 17. 
                        Table: 17 Drug content of aceclofenac in all formulations 
   Formulation code Drug content (in %) 
             F1        76.89±0.7128  
             F2        66.5±0.7071  
             F3        70.55  ±0.7805 
             F4        67.68±1.2583 
             F5        72.14±1.1185  
             F6        74.20±1.1145 
             F7         87.09±3.7390 
             F8         82.5±2.121 
             F9          78.37±1.4913 
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                                        Fig. 14 Drug content of aceclofenac in all formulations                                                  
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                                                  PERCENTAGE PRACTICAL YIELD 
Percentage practical yield of aceclofenac in all the formulations (F1 to F9) were 
shown from 89.09±0.291 to 95.46±0.9799 respectively. 63 As shown in table 18. 
                         Table: 18 Drug content of aceclofenac in all formulations 
Formulation code % Practical yield 
             F1         92.71±1.0651 
             F2         89.09±0.291 
             F3         94.7±0.6420 
             F4         91.08±0.305 
             F5         90.12±1.307 
             F6         90.82±0.3614 
             F7         95.46±0.9799          
             F8         93.51±0.1937 
             F9          92.77±0244 
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                                    Fig. 15 Drug content of aceclofenac in all formulations 
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PHASE SOLUBILITY STUDY 
                        Table: 19 Solubility of aceclofenac in PEG6000 solution                                       
Sl.no Concentration of PEG6000 
(%w/v) 
Solubility of  
aceclofenac in 
PEG6000 solution 
(mg/ml) 
1               0       0.2125 
2           0.0025       0.3621 
3           0.0050      0.5410 
4           0.010      1.6539 
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                           Fig.17 Solubility of aceclofenac in PEG6000 solution                                       
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             Table: 20 Solubility of aceclofenac in PVP solution 
S.no Concentration of PVP 
(%w/v) 
Solubility of  
aceclofenac in PVP 
solution (mg/ml) 
1             0         0.1965 
2            0.0025        0.3365 
3            0.0050        0.5110 
4            0.010        1.6393 
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                             Fig.18 Solubility of aceclofenac in PVP solution                                     
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            Table: 21 Solubility of aceclofenac in HPMC solution                                    
  S.no Concentration of 
HPMC (%w/v) 
Solubility of  aceclofenac 
in HPMC solution (mg/ml) 
      1           0           0.1652 
       2        0.0025           0.2899 
       3        0.0050           0.4753 
      4        0.010           1.5861 
 
 
                                   Fig.19 Solubility of aceclofenac in HPMC solution                                        
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COMPARATIVE PHASE SOLUBILITY 
Phase solubility study was carried out in order in to ascertain effect of carriers on 
the solubility characteristics of aceclofenac. Solubility of aceclofenac was increased as 
the concentration of carriers increased64. The solubility of aceclofenac was minimal in 
methanol and increased approximately eight fold at 0.01%w/v of PEG6000 in methanol. 
These data indicates that PEG6000 in methanol solubility of aceclofenac was greatly 
enhanced possibly due to the solvent effect of PEG6000. 
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Fig.20 Comparative phase solubility 
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IN-VITRO DISSOLUTION STUDIES 
The aceclofenac solid dispersions were prepared by using with hydrophilic 
carriers like PEG6000, PVP and HPMC, in-vitro drug release studies were carried out in 
trail (n=3) basis for total 9 formulations.   
The release of aceclofenac solid dispersions was studied in 900 ml of pH 6.8 
phosphate buffer upto 90 min as dissolution medium using USP II (paddle) dissolution 
apparatus at 50 rpm and 370±0.5 0C. Drug content was determined by UV-
Spectrophotometer at 275 nm. Cumulative percentage of drug release was calculated by 
using an equation obtained from a standard curve. The dissolution studies were performed 
3 times for a period of 90 min, where Mean±S.D values were calculated.  The results of 
studies were shown in Tables 22-41. 
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       Table: 22 In-vitro dissolution profile for solid dispersion pure aceclofenac 
 
Time 
(min) 
Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 4.71 4.70 4.78 4.73±0.0435 
20 11.03 10.50 10.56 10.69±0.2902 
30 12.34 12.42 12.52 12.42±0.0901 
40 14.12 14.19 14.09 14.13±0.0513 
50 17.64 17.62 17.39 17.55±0.1389 
60 25.73 24.15 25.15 25.01±0.7992 
70 29.07 28.93 29.10 29.03±0.0907 
80 33.58 33.34 34.09 33.67±0.3830 
90 37.59 36.14 38.19 37.30±1.0539 
 
  Table: 23 Kinetic data for in-vitro release rates solid dispersion pure aceclofenac 
Time 
(min) 
square root 
of time 
log time 
cumulative 
%  drug 
release 
log 
cumulative %  
drug release 
cumulative 
%  drug 
remaining 
log 
cumulative 
%drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 4.73 0.67486 95.27 1.97895 
20 4.47213 1.30102 10.69 1.02897 89.31 1.95090 
30 5.47722 1.47712 12.42 1.09412 87.58 1.94240 
40 6.32455 1.60205 14.13 1.15014 85.87 1.93384 
50 7.07106 1.69897 17.15 1.23426 82.85 1.91829 
60 7.74596 1.77815 25.01 1.39811 74.99 1.87500 
70 8.36660 1.84509 29.03 1.46284 70.97 1.85107 
80 8.94427 1.90308 33.67 1.52724 66.33 1.82170 
90 9.48683 1.95424 37.30 1.57170 62.7 1.79726 
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Fig.P (a) 
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Fig. P (d) 
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          Table: 24 In-vitro dissolution profile for solid dispersion F1 formulation 
Time 
(min) 
Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 30.15 29.70 30.90 30.25 ± 0.606 
20 38.20 38.15 37.92 38.09±0.1493 
30 45.25 44.51 42.35 44.03 ±1.506 
40 53.84 52.09 51.89 52.60±1.0727 
50 59.57 58.95 59.00 59.17±0.3443 
60 67.25 65.70 66.31 66.42±0.7808 
70 74.09 72.12 73.15 73.12±0.9853 
80 79.23 78.15 77.15 78.17±1.1784 
90 84.29 79.13 83.25 82.22±2.7289 
               
  Table: 25 Kinetic data for in-vitro release rates of solid dispersion F1 formulation    
Time 
(min) 
square root 
of time 
log time 
cumulative 
%  drug 
release 
log 
cumulative % 
drug release 
cumulative 
% drug 
remaining 
log 
cumulative
% drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 30.25 1.48072 69.75 1.8435 
20 4.47213 1.30102 38.09 1.58081 61.91 1.79176 
30 5.47722 1.47712 44.03 1.64374 55.97 1.74795 
40 6.32455 1.60205 52.60 1.72098 47.4 1.67577 
50 7.07106 1.69897 59.17 1.77210 40.83 1.61097 
60 7.74596 1.77815 66.42 1.82229 33.58 1.52608 
70 8.36660 1.84509 73.12 1.86403 26.88 1.42942 
80 8.94427 1.90308 78.17 1.89276 21.83 1.33905 
90 9.4683 1.95424 82.22 1.91497 17.78 1.24993 
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Fig.1 (c) 
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          Table: 26 In-vitro dissolution profile for solid dispersion F2 formulation 
Time(min) Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 40.08 41.23 42.19 41.16 ±1.0564 
20 51.90 50.98 49.67 50.85±1.1206 
30 54.01 53.19 54.23 53.81±0.5480 
40 57.38 56.29 55.55 56.40±0.9205 
50 58.38 57.09 58.09 57.85±0.6767 
60 61.38 61.08 59.15 60.53±1.2102 
70 70.81 69.15 68.34 69.43±1.2591 
80 73.15 72.12 74.09 73.12±0.9853 
90 76.39 75.19 76.16 75.91±0.6368 
            
   Table: 27 Kinetic data for in-vitro release rates of solid dispersion F2 formulation       
Time 
(min) 
square root 
of time 
log time 
cumulative 
% drug 
release 
log 
cumulative 
% drug 
release 
cumulative 
% drug 
remaining 
log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 41.16 1.61447 58.84 1.76967 
20 4.47213 1.30102 50.85 1.70629 49.15 1.69152 
30 5.47722 1.47712 53.81 1.73086 46.19 1.66454 
40 6.32455 1.60205 56.40 1.75127 43.6 1.63948 
50 7.07106 1.69897 57.85 1.76230 42.15 1.62479 
60 7.74596 1.77815 60.53 1.78197 39.47 1.59626 
70 8.36660 1.84509 69.43 1.84154 30.57 1.48529 
80 8.94427 1.90308 73.12 1.86403 26.88 1.42942 
90 9.48683 1.95424 75.91 1.88029 24.09 1.38183 
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Fig.2 (a) 
 
         
Fig.2 (b) 
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Fig.2 (d) 
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             Table: 28 In-vitro dissolution profile for solid dispersion F3 formulation 
Time 
(min) 
Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 25.30 24.90 25.95 25.38±0.5299 
20 37.29 38.51 38.91 38.23±0.8438 
30 39.70 40.75 39.15 39.86±0.8129 
40 42.78 43.04 42.80 42.87±0.1446 
50 49.10 49.81 48.75 49.22±0.5400 
60 55.37 55.25 54.65 55.09±0.3857 
70 59.43 58.50 59.85 59.26±0.6908 
80 64.80 64.34 65.01 64.71±0.3426 
90 69.15 69.95 70.03 69.71±0.4866 
                                 
   Table: 29 Kinetic data for in-vitro release rates of solid dispersion F3 formulation   
Time 
(min) 
square root 
of time 
log time 
cumulative 
%drug 
release 
log 
cumulative % 
drug release 
cumulative 
% drug 
remaining 
log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 25.38 1.40277 74.72 1.87343 
20 4.47213 1.30102 38.23 1.58240 61.77 1.79077 
30 5.47722 1.47712 39.86 1.60053 60.14 1.77916 
40 6.32455 1.60205 42.87 1.63215 57.13 1.75686 
50 7.07106 1.69897 49.22 1.69214 50.78 1.70569 
60 7.74596 1.77815 55.09 1.74107 44.91 1.65234 
70 8.836660 1.84509 59.26 1.77276 40.74 1.61002 
80 8.94427 1.90308 64.71 1.81097 35.29 1.54765 
90 9.48683 1.95424 69.71 1.84329 30.29 1.48129 
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Fig.3 (a) 
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Fig.3 (d) 
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          Table: 30 In-vitro dissolution profile for solid dispersion F4 formulation 
Time(min) Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 14.92 14.70 15.44 15.02±0.3810 
20 24.67 24.42 24.55 24.55±0.1245 
30 38.66 37.13 37.65 37.81±0.7792 
40 41.14 38.88 41.23 40.51±1.4081 
50 51.37 46.75 48.20 48.77±2.3599 
60 58.54 54.62 56.01 56.39±1.9864 
70 62.60 60.48 61.91 61.66±1.0828 
80 69.02 66.52 67.50 67.68±1.2583 
90 72.37 70.92 73.12 72.14±1.1185 
                              
      Table: 31 Kinetic data for in-vitro release rates of solid dispersion F4 formulation     
Time 
(min) 
square root 
of time 
log time 
cumulative 
% drug 
release 
log 
cumulative %  
drug release 
cumulative 
% drug 
remaining 
log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 15.02 1.17666 84.98 1.92931 
20 4.47213 1.30102 24.55 1.39005 75.45 1.87765 
30 5.47722 1.47712 37.18 1.57030 62.82 1.79809 
40 6.32455 1.60205 40.15 1.60368 59.85 1.77706 
50 7.07106 1.69897 48.77 1.68815 51.23 1.70952 
60 7.74596 1.77815 56.39 1.75120 43.61 1.63958 
70 8.36660 1.84509 61.66 1.79000 38.34 1.58365 
80 8.94427 1.90308 67.68 1.83046 32.32 1.50947 
90 9.48683 1.95424 72.14 1.85817 27.86 1.44498 
 
 
80 
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Fig.4 (d) 
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         Table: 32 In-vitro dissolution profile for solid dispersion F5 formulation 
Time(min) Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 30.78 28.35 29.51 29.55± 1.21541 
20 41.41 38.88 41.23 40.51±1.4116 
30 46.29 45.68 46.17 46.05±0.3231 
40 51.02 48.84 49.49 49.78±1.1192 
50 60.24 57.52 58.21 58.66±1.4149 
60 66.49 64.51 66.07 65.69±1.0432 
70 74.14 72.76 71.82 72.90±1.1688 
80 80.71 77.45 79.56 79.24±1.16568 
90 82.40 81.43 83.04 82.29±0.8078 
                            
    Table: 33 Kinetic data for in-vitro release rates of solid dispersion F5 formulation     
Time 
(min) 
square 
root of 
time 
log time 
cumulative 
% drug 
release 
log cumulative 
% drug 
release 
cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 29.55 1.47055 70.45 1.84788 
20 4.47213 1.30102 40.51 1.60756 59.49 1.77444 
30 5.47722 1.47712 46.05 1.66322 53.95 1.73199 
40 6.32455 1.60205 49.78 1.69705 50.22 1.700087 
50 7.07106 1.69897 58.66 1.76834 41.34 1.61637 
60 7.74596 1.77815 65.69 1.81749 34.31 1.53542 
70 8.36660 1.84509 72.90 1.86272 27.1 1.43296 
80 8.94427 1.90308 79.24 1.89894 20.76 1.31722 
90 9.48683 1.95424 82.29 0.35983 17.71 1..24821 
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Fig.5 (a) 
0
20
40
60
80
100
0 20 40 60 80 100%
 d
ru
g 
re
le
as
e 
Time(min) 
Percentage drug release profile 
 
Fig.5 (b) 
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Fig.5 (d) 
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Table: 34 In-vitro dissolution profile for solid dispersion F6 formulation 
Time(min) Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 37.30 38.01 37.15 37.48±0.4593 
20 42.78 42.10 43.45 42.77±0.6750 
30 46.04 44.99 45.94 45.65±0.5795 
40 49.10 49.34 48.15 48.86±06293 
50 55.37 54.19 55.90 55.15±0.8753 
60 59.43 58.19 59.59 59.07±0.7662 
70 64.13 64.09 65.32 64.51±0.6988 
80 69.17 68.15 68.99 68.77±0.5444 
90 76.51 77.41 76.44 76.79±0.5437 
                                        
  Table: 35 Kinetic data for in-vitro release rates of solid dispersion F6 formulation     
Time 
(min) 
square root 
of time 
log time 
cumulative 
% drug 
release 
log 
cumulative 
% drug 
release 
cumulative 
% drug 
remaining 
Log 
cumulative 
% drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 37.48 1.57379 62.52 1.79601 
20 4.47213 1..30102 42.77 1.63113 57.23 1.75762 
30 5.47722 1.47712 45.65 1.65944 54.35 1.73519 
40 6.32455 1.60205 48.86 1.68895 51.14 1.70876 
50 7.07106 1.69897 55.15 1.74154 44.85 1.65176 
60 7.74596 1.77815 59.05 1.77121 40.95 1.61225 
70 8.36660 1.84509 64.51 1.80962 35.49 1.55010 
80 8.94427 1.90308 68.77 1.83739 31.23 1.49457 
90 9.48683 1.95424 76.79 1.88530 23.21 1.36567 
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Fig.6 (d) 
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            Table: 36 In-vitro dissolution profile for solid dispersion F7 formulation 
Time(min)  Trail 1    Trail 2   Trail3     Mean ± SD 
0 0 0 0 0 
10 33.42 34.20 33.06 33.56±0.5827 
20 39.70 39.15 40.45 39.86±0.8129 
30 47.14 46.50 47.82 47.15±0.6601 
40 55.93 56.02 54.29 55.41±0.9738 
50 6.70 62.04 63.15 62.29±0.7583 
60 69.28 69.32 71.32 69.96±1.1664 
70 78.90 77.13 76.23 77.42±0.3584 
80 84.24 84.32 85.14 84.56±0.4981 
90 97.53 96.25 96.85 96.21±0.6404 
                                  
 Table: 37 Kinetic data for in-vitro release rates of solid dispersion F7 formulation     
Time 
(min) 
square root 
of time 
log time cumulative 
% drug 
release 
Log 
cumulative % 
drug release 
cumulative 
%  drug  
remaining 
log  
cumulative 
% drug  
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 33.56 1.52582 66.44 1.82242 
20 4.47213 1.30102 39.86 1.60053 60.14 1.77916 
30 5.47722 1.47712 47.15 1.67348 52.85 1.72304 
40 6.32455 1.60205 55.41 1.74358 44.59 1.64923 
50 7.07106 1.69897 62.29 1.79441 37.71 1.57645 
60 7.74596 1.77815 69.96 1.84484 30.04 1.47769 
70 8.36660 1.84509 77.42 1.88885 22.58 1.35372 
80 8.94427 1.90308 84.56 1.92716 15.44 1.18864 
90 9.48683 1.95424 96.21 1.98322 3.79 0.57863 
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Fig.7 (d) 
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          Table: 38 In-vitro dissolution profile for solid dispersion F8 formulation 
Time(min) Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 44.44 42.29 45.37 44.03±1.5828 
20 49.23 46.97 50.49 48.90±1.7853 
30 55.20 54.32 55.76 55.10±0.7248 
40 61.70 60.28 60.60 60.86±0.7413 
50 68.94 68.23 70.31 69.16±1.0576 
60 76.51 77.41 76.44 76.79±0.5437 
70 83.52 87.02 85.46 85.33±0.7578 
80 89.80 89.01 91.56 90.12±0.3077 
90 93.14 93.67 93.76 93.52±.3384 
           
   Table: 39 Kinetic data for in-vitro release rates of solid dispersion F8 formulation     
Time 
(min) 
square root 
of time 
log time cumulative 
% drug 
release 
log 
cumulative % 
drug release 
cumulative 
% drug  
remaining 
log  
cumulative 
%  drug  
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 44.03 1.64374 55.97 1.74795 
20 4.47213 1.30102 48.90 1.68930 51.1 1.70842 
30 5.47722 1.47712 55.10 1.74115 44.9 1.65224 
40 6.32455 1.60205 60.86 1.78433 39.14 1.59262 
50 7.07106 1.69897 69.16 1.83985 30.84 1.48911 
60 7.74596 1.77815 76.79 1.88530 23.21 1.36567 
70 8.36660 1.84509 85.33 1.93110 14.67 1.16643 
80 8.94427 1.90308 90.12 1.95482 9.88 0.99475 
90 9.48683 1.95424 93.52 1.97090 6.48 0.81157 
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Fig.8 (a) 
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          Table: 40 In-vitro dissolution profile for solid dispersion F9 formulation 
Time(min) Trail 1 Trail 2 Trail3 Mean ± SD 
0 0 0 0 0 
10 30.82 31.14 30.77 30.91±0.200 
20 36.55 35.98 37.08 36.53±0.550 
30 42.91 44.05 43.35 44.43±0.574 
40 64.46 64.08 63.80 64.11±0.331 
50 70.24 69.63 70.16 70.01±0.331 
60 75.22 74.81 75.39 75.14±0.296 
70 80.08 79.77 80.29 82.04±0.261 
80 86.88 87.30 87.74 87.30±0.430 
90 91.09 90.77 91.38 91.08±0.305 
 
   Table: 41 Kinetic data for in-vitro release rates of solid dispersion F9 formulation     
Time 
(min) 
square root 
of time 
log time cumulative 
%of drug 
release 
log cumulative 
%of  drug 
release 
cumulative 
%of  drug 
remaining 
log  
cumulative 
%of  drug 
remaining 
0 0 0 0 0 100 2 
10 3.16227 1 30.91 1.40099 69.09 1.83941 
20 4.47213 1.30102 36.53 1.56264 63.47 1.80256 
30 5.47722 1.47712 44.43 1.64767 55.57 1.74484 
40 6.32455 1.60205 64.11 1.80692 35.89 1.55497 
50 7.07106 1.69897 70.01 1.84516 29.99 1.47697 
60 7.74596 1.77815 75.14 1.87587 24.86 1.39550 
70 8.36660 1.84509 82.04 1.91402 17.96 1.25430 
80 8.94427 1.90308 87.30 1.94101 12.7 1.10380 
90 9.48683 1.95424 91.08 1.9594 8.92 0.95036 
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   Table: 42 In-vitro cumulative percentage of drug release of F1 to F9 formulations 
Time 
(min) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
10 30.25 41.16 25.38 15.02 29.55 37.48 33.56 44.03 30.91
20 38.09 50.85 38.23 24.55 40.51 42.77 39.86 48.90 36.53
30 44.03 53.81 39.86 37.81 46.05 45.65 47.15 55.10 44.43
40 52.60 56.40 42.87 40.51 49.78 48.86 55.41 60.86 64.11
50 59.17 57.85 49.22 48.77 58.66 55.15 62.29 69.16 70.01
60 66.42 60.53 55.09 56.39 65.69 59.07 69.96 76.79 75.14
70 73.12 69.43 59.26 61.66 72.24 64.51 77.42 85.33 82.04
80 78.17 73.12 64.71 67.68 79.24 68.77 84.56 90.12 87.30
90 82.22 75.19 69.71 72.14 82.29 76.79 96.21 93.52 91.08
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  Table: 43 Kinetics of aceclofenac solid dispersions  
Formulation 
code 
Zero order 
(“r”values) 
First order 
(“r” 
values) 
Higuchi 
(“r” values) 
       Korsemeyar-Peppas
(“r” values)         “n” 
values 
Pure drug 0.9265 0.9728 0.9341 0.9819 0.2579 
F1 0.9733 0.9879 0.9895 0.9972 0.3649 
F2 0.768 0.9069 0.9316 0.9639 0.424 
F3 0.8568 0.9656 0.9758 0.9987 0.3918 
F4 0.9694 0.9882 0.9838 0.9932 0.3318 
F5 0.9228 0.9805 0.9833 0.9932 0.3318 
F6 0.8351 0.9810 0.9487 0.9961 0.4304 
F7 0.9554 0.9594 0.9834 0.9879 0.3643 
F8 0.8746 0.9557 0.969 0.9916 0.347 
F9 0.9277 0.9837 0.9708 0.9961 0.4438 
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In- vitro release studies reveal that there is marked increase in the dissolution rate 
of aceclofenac from all the solid dispersions when compared to pure aceclofenac itself. 
From the in-vitro drug release profile, it can be seen that formulation F-7 containing 
PEG6000 and PVP (1:1:1 ratio of drug: PEG6000: PVP) shows higher dissolution rate 
compared with other formulations. This may be attributed to the increase in drug 
wettability, conversion to amorphous form and solubilization of the drug due to 
hydrophilic carrier. The increase in dissolution rate is in the order of PEG6000:PVP > 
PEG6000:HPMC > PVP:HPMC. In the case of solid dispersions of aceclofenac with 
PEG6000, PVP, and HPMC ratio of 1:1:1, the dissolution rate of drug increased while in 
the case of those prepared in the ratio of 1:1 and 1:2 the dissolution rate of drug was 
decreased. This might be due to formation of viscous layer around the drug particles 
leading to decrease in the dissolution rate. The increase in dissolution rate is in the order 
of F7 >F8>F9 >F1>F5>F6>F2 >F4>F3. The regression coefficient (r) values for 
formulations F1 to F9 model that gave higher ‘r’ value was considered as best fit model. 
The r values were found to be higher in the first order model (0.9804, 0.9805, 0.9569, 
0.9656, 0.9805, 0.9865, 0.9850, 0.9849, 0.9557, 0.9837) than those in the zero order 
model (0.9794,0.9265,0.868,08568,0.9228, 0.9328,0.9252,0.9454,0.8746,0.9277) with all 
the solid dispersion ( pure aceclofenac, F1, F2, F3, F4, F5, F6, F7, F8 and F9 
respectively) indicating that the dissolution of aceclofenac as such and from all the solid 
dispersion followed first order kinetics. Based on ‘r’ values (greater than 0.9527) it was 
also observed that all the solid dispersion followed Higuchi matrix suggesting the drug 
release is by diffusion. Korsemeyar-Peppa’s suggest Fickian diffusion release which 
shows that the formulations also appear to release the drug by erosion mechanism and the 
release is drug dissolution limited. FTIR spectroscopic studies conducted for possible 
drug: carrier interactions FTIR spectra of pure drug aceclofenac, PEG6000, PVP, HPMC 
and aceclofenac with its solid dispersion were obtained which shows all the characteristic 
peaks of aceclofenac and carriers were present in the solid dispersions; thus indicating no 
significant evidence of chemical interaction between drug and carrier, which confirms the 
stability of drug with its solid dispersion. 
 
The solid dispersions of the water- insoluble drug aceclofenac were successfully 
prepared by solvent evaporation technique using hydrophilic carriers. The in-vitro 
dissolution test showed a significant increase in the dissolution rate of solid dispersions as 
compared with pure aceclofenac. Mechanisms involved are solubilization and improved 
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wetting of the drug in the hydrophilic carriers rich microenvironment formed at the 
surface of drug crystals after dissolution rate. The crystallinity of the drug was reduced in 
solid dispersion formulation with polymers i.e. PEG6000 and PVP combination. 
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9.0 CONCLUSION 
Aceclofenac solid dispersions were prepared using PEG 6000, PVP and HPMC as 
carriers to improve the solubility of aceclofenac. Solid dispersion technique found to be 
effective in increasing the aqueous solubility of aceclofenac. In-vitro dissolution studies 
showed that in the dispersion systems containing the carriers, dissolution of aceclofenac 
were retarded, which attributed to ionic interaction and gel forming respectively. But 
solid dispersion containing as a carrier, gave faster dissolution rates than the pure drug. 
Solid dispersion of formulation (F7) aceclofenac, PEG 6000 and PVP combination 
prepared in (1:1:1) ratio showed excellent solubility and the dissolution rate found to be 
96.21% was selected as the best formulation in this study. All the formulations described 
by the first order kinetics and the “n” values of peppa’s suggest Fickian release 
mechanism. More ever , the crystallinity of the drug was reduced in solid dispersion 
formulation with carriers, results from FTIR spectroscopy concluded that there was no 
well-defined interaction between aceclofenac and carriers .Finally it could be concluded 
that solid dispersion of aceclofenac using hydrophilic carriers would improve the aqueous 
solubility,  dissolution rate and thereby enhancing its systemic availability. 
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